References
- Suhoski, MM, Golovina TN, Aqui NA, Tai VC, Varela-Rohena A, Milone, MC, . Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol. Ther. 2007;15:981–8.
- Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, . Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Developmental Committee of the European Group for Blood and Marrow Transplantation. Lancet. 2008;371:1579–86.
- Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B, Arvidson J, . Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia. 2007;21:1733–8.
- Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with meta-static melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA. 2002;99:16168–73.
- Bollard CM, Gottschalk S, Leen AM, Weiss H, Straathof KC, Carrum G, . Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007;110:2838–45.
- DL DiGiusto, LJN Cooper. Preparing clinical-grade antigen-specific T cells for adoptive immunotherapy trials. Cytotherapy. 2007;9:613–29.
- Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8:299–308.
- Levine BL, Humeau LM, Boyer J, MacGregor RR, Rebello T, Lu X, . Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA. 2006;103:17372–7.
- Cooley S, Gada P, McKenna D, McCullar V, Fautsch S, Verneris M, . Successful haploidentical hematopoietic cell engraftment using a non-myeloablative preparative regimen including natural killer (NK) cells. 50th ASH Annual Meeting Abstracts. Blood. 2008;112:307.
- Berg M, Lundqvist A, McCoy P, Leigh S, Fan Y, Tawab A, Childs R. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy. 2009;11:341–55.
- Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, . Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 2004;64:5934–7.
- Whiteside TL, Piazza P, Reiter A, Stanson J, Connolly NC, Rinaldo RR, . Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection. Clin. Vaccine Immunol. 2009;16:233–40.
- Love Z, Wang F, Dennis J, Awadallah A, Salem N, Lin Y, . Imaging of mesenchymal stem cell transplant by bioluminescence and PET. J Nucl Med. 2007;48:2011–20.
- Ahrens ET, Flores R, Xu H, Morel PA. In vivo imaging platform for tracking immunotherapeutic cells. Nat. Biotechnol. 2005;23:983–7.
- O’Gorman WE, Dooms H, Thorne SH, Kuswanto WF, Simonds EF, Krutzik PO, . The initial phase of an immune response functions to activate regulatory T cells. J Immunol. 2009;183:332–9.
- Krutzik PO, Nolan GP. Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytometry. 2003;55:61–70.